Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of
the metal, its oxidation state, the types and number of coordinated ligands and the …

The chicken chorioallantoic membrane (CAM) is a simple, highly vascularized
extraembryonic membrane, which performs multiple functions during embryonic …

The discovery of cisplatin's antitumor activity in 1969 prompted the search for novel metal-
containing complexes as potential anticancer drugs. Among these novel complexes, metal N …

Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers
and are applied in the majority of anticancer chemotherapeutic regimens. The success of …

The popularity of RAPTA-C in in vivo studies has steered the way for complexes of the type
[Ru (η 6-arene)(X)(Y)(Z)] n+ (where X, Y and Z are monodentate ligands) to be developed …

Drug resistance remains the major cause of cancer treatment failure especially at the late
stage of the disease. However, based on their versatile chemistry, metal and metalloid …

Anti-angiogenic cancer therapies possess immune-stimulatory properties by counteracting
pro-angiogenic molecular mechanisms. We report that tumor endothelial cells ubiquitously …

After nearly 20 years of research on the use of ruthenium in the fight against cancer, only two
Ru (III) coordination complexes have advanced to clinical trials. During this time, the field …